The companies will build and screen novel DNA-encoded libraries for use by Pfizer in its drug discovery efforts.
Illumina's partnership with the Human Vaccines Project and Vanderbilt looks to crunch data sets billions of times larger than human genome.
The partners will develop biomarkers and assays to evaluate non-alcoholic steatohepatitis, a disease characterized by liver scarring due to inflammation.
The Harvard spinout is commercializing inDrop single-cell sequencing technology developed by Allon Klein.
The collaborators are each providing funding and samples, and plan to study about 100 patients with a subset of Castleman disease to identify biomarkers.
The potential cross-Pacific partnership could help the Seattle-based research institute discover and define cell types in the human brain.
GATC will provide next-generation sequencing services for Constance research projects, and they will work together to further develop sequencing methods.
Seven Bridges will add Spatial Transcriptomics' histology and gene expression visualization tool to its platform by the end of the year.
Through this Alnylam-funded program, Invitae will perform free testing for US patients suspected to have hereditary ATTR amyloidosis or a family history of it.
The firms will use the FoundationOne assay to characterize tumors and their microenvironment to find predictive measures of response to cancer immunotherapies.
At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.
In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.
Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.
People around the globe took to the streets to support science — some with signs.